The Loramyc® mucoadhesive gingival tablet (brand name Oravig® in the USA) is the first product developed and registered by BioAlliance Pharma.
Loramyc® is based on the Lauriad™ technology, an oral delivery system allowing for a novel way of targeting the mucous membranes, releasing rapidly and on a continued basis a quantity of active pharmaceutical ingredient that impregnates the infected tissues, without systemic transfer. Loramyc® is the first anti-mycosis specialty to use this adhesive gingival technology.
The gingival tablet has been designed to remain in place in the oral cavity (in the canine fossa) where it gradually releases the active pharmaceutical ingredient. The gingival tablet disintegrates when release has ended. The tablet matrix, which gives the tablet its mucoadhesive properties, consists of a milk protein concentrate. This natural protein excipient gradually becomes hydrated and sticks to the proteins of the mucous surface, and then releases the active pharmaceutical ingredient on a prolonged basis. This excipient has been chosen for its long-lasting adhesive qualities, and it is moreover widely used in the food industry.
Miconazole Lauriad™ (Oravig®) is indicated for the treatment of oropharyngeal candidiasis (in Europe, this indication is restricted to immune compromised patients). Oropharyngeal candidiasis is a fungal infection caused by candida which may develop in immune compromised patients, notably cancer patients being treated by chemotherapy or radiation therapy and HIV-infected patients). If left untreated in these fragile patients, oropharyngeal candidiasis may invade the esophagus or further progress to induce systemic complications.
BioAlliance Pharma has obtained its first marketing authorisation for Loramyc® in France in October 2006. Today, the product is registered in 26 European countries (including Switzerland), in the United States and in South Korea.
Loramyc® is sold on the French market by Therabel Lucien Pharma Laboratories at a public price of € 71.55 per bottle of 14 tablets. It is entitled to a 65% reimbursement.